The PML/RARA t(15:17) Qualitative - PCR test is a diagnostic tool used to detect a specific genetic abnormality associated with a type of leukemia called acute promyelocytic leukemia (APL). This genetic abnormality involves a translocation between chromosomes 15 and 17, resulting in the fusion of two genes: PML (promyelocytic leukemia) and RARA (retinoic acid receptor alpha). The PML/RARA fusion gene is considered a hallmark of APL and plays a critical role in its development.
The PML/RARA t(15:17) Qualitative - PCR test utilizes a technique called polymerase chain reaction (PCR) to detect the presence of the PML/RARA fusion gene in the DNA extracted from blood or bone marrow samples. By identifying this genetic abnormality, the test aids in confirming the diagnosis of APL and guiding appropriate treatment decisions.
Get your pml-rara qualitative test done at sprint diagnostics near you in Hyderabad, Schedule your test today to get accurate and fast results.
The PML/RARA t(15:17) Qualitative - PCR test detects the presence of the PML/RARA fusion gene in your blood or bone marrow sample. Its main purpose is to confirm the diagnosis of acute promyelocytic leukemia (APL) by identifying this specific genetic abnormality.
In the context of the PML/RARA t(15:17) Qualitative - PCR test, a positive result indicates the presence of the PML/RARA fusion gene, confirming the diagnosis of acute promyelocytic leukemia (APL). A negative result suggests the absence of the fusion gene.
No specific precautions are required before or after the PML/RARA t(15:17) Qualitative - PCR test. However, it is always advisable to follow any instructions provided by your healthcare provider regarding medications, lifestyle modifications, or other relevant aspects of your care.
No specific fasting or preparation is required for the PML/RARA t(15:17) Qualitative - PCR test. You can follow your regular eating and drinking habits before the test.
The PML/RARA t(15:17) Qualitative - PCR test is crucial in diagnosing acute promyelocytic leukemia (APL). It helps confirm the presence of the PML/RARA fusion gene, which is a characteristic genetic abnormality in APL. This information is essential for accurate diagnosis, determining the prognosis, and guiding appropriate treatment strategies.